A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.

Cash BD, Lu M, Lembo A, Feuerstadt P, Nguyen L, Terasawa E, Ayyagari R, Du S, Pi S, Westermeyer B, Terreri B, Boules M, Moshiree B

Journal of managed care & specialty pharmacy1 Oct 2024Cited by 4 (Europe PMC)

PMID39321115PMCIDPMC11424913DOI10.18553/jmcp.2024.30.10.1136PepBankPUB-39321115

Source link PubMedAsk about this study

Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanObservational studyOther
In adults with CIC, plecanatide was associated with higher adjusted discontinuation hazard than prucalopride after 2 months (HR 1.31, 95% CI 1.13-1.51, P < 0.001).
In plain wordsPlecanatide was linked to higher discontinuation hazard than prucalopride after two months.
Peptide
Plecanatide
Outcome
IncreaseDiscontinuation after 2 months
Study
n: not reported in source
Comparator
Prucalopride
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Adjusted hazard ratio for discontinuation
1.31 HR
Plecanatide vs prucalopride, after 2 months
95% CI of adjusted hazard ratio for discontinuation
1.13 to 1.51 HR
Plecanatide vs prucalopride, after 2 months
Source sentences
Summary
After adjusting for confounding factors, the HRs for discontinuation were significantly higher for all comparator medications compared with prucalopride after 2 months (HR [95% CI]: lubiprostone, 1.70 [1.48-1.95]; linaclotide, 1.25 [1.10-1.41]; plecanatide, 1.31 [1.13-1.51], all P < 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020).
Summary · context
Inclusion criteria were patients (aged ≥18 years) with at least 1 prescription fill for prucalopride, lubiprostone, linaclotide, or plecanatide on or after April 2, 2019 (commercial availability of prucalopride), and at least 1 constipation-related diagnosis code.
Report a problemFND-3932111501
02HumanObservational studyOther
In adults with CIC, unadjusted mean PDC was 0.48 (SD 0.29) with plecanatide versus 0.53 (SD 0.32) with prucalopride (P = 0.98).
In plain wordsPlecanatide had numerically lower days covered than prucalopride, with no significant difference.
Peptide
Plecanatide
Outcome
DecreaseMean proportion of days covered
Study
n: not reported in source
Comparator
Prucalopride
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Unadjusted mean PDC
0.48 PDC
Plecanatide
SD of PDC
0.29 PDC
Plecanatide
Unadjusted mean PDC
0.53 PDC
Prucalopride
SD of PDC
0.32 PDC
Prucalopride
Source sentences
Summary
The unadjusted mean (SD) PDC was 0.53 (0.32) with prucalopride compared with 0.41 (0.31); P less than 0.001 with lubiprostone, 0.48 (0.31), P less than 0.05 with linaclotide, and 0.48 (0.29), P = 0.98 with plecanatide.
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020).
Summary · context
Inclusion criteria were patients (aged ≥18 years) with at least 1 prescription fill for prucalopride, lubiprostone, linaclotide, or plecanatide on or after April 2, 2019 (commercial availability of prucalopride), and at least 1 constipation-related diagnosis code.
Report a problemFND-3932111502
03HumanObservational studyOther
In adults with CIC, plecanatide was associated with lower odds of PDC of at least 80% than prucalopride (OR 0.70, 95% CI 0.53-0.93, P = 0.015).
In plain wordsPlecanatide was linked to lower odds of high adherence than prucalopride.
Peptide
Plecanatide
Outcome
DecreasePDC of at least 80%
Study
n: not reported in source
Comparator
Prucalopride
Outcome group
Treatment adherence and retention · Whole body
Studied dose
Dose not stated
Measurements
Odds ratio for PDC of at least 80%
0.7 OR
Plecanatide vs prucalopride
95% CI of odds ratio for PDC of at least 80%
0.53 to 0.93 OR
Plecanatide vs prucalopride
Source sentences
Summary
The comparator medications were all associated with lower odds of achieving PDC of at least 80% relative to prucalopride (odds ratio [95% CI]: lubiprostone, 0.52 [0.40-0.69], P P = 0.009; plecanatide, 0.70 [0.53-0.93], P = 0.015).
2 context sentences(design, population, supporting numbers)
Summary · context
This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020).
Summary · context
Inclusion criteria were patients (aged ≥18 years) with at least 1 prescription fill for prucalopride, lubiprostone, linaclotide, or plecanatide on or after April 2, 2019 (commercial availability of prucalopride), and at least 1 constipation-related diagnosis code.
Report a problemFND-3932111503

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 2
27 Oct 2026, 16:37 UTC
Study data updated · source update from Europe PMC
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.